吡格列酮对2型糖尿病大鼠血清炎症介质和糖耐量的影响

目的探讨吡格列酮对2型糖尿病大鼠炎症因子及其糖耐量水平的影响。方法8周龄健康Wistar大鼠，用链脲菌素（STZ）加高脂肪高热卡饮食诱导2型糖尿病大鼠模型，将糖尿病大鼠随机分为2组：糖尿病组（n=10）、吡格列酮组（n=10，10mg·kg-1．d-1，灌胃），健康Wistar大鼠作为对照组（n=10），糖尿病组和对照组给予同体积生理盐水灌胃，8周后分别测定空腹血糖（FBG）和胰岛素水平（FINS），进行口服葡萄糖耐量试验（OGTT），计算胰岛素抵抗指数（HOMA。IR），测定大鼠血清中白介素1B（IL-1B）、白介素6（IL．6）、肿瘤坏死因子α（TNF-α）、急相反应蛋白C（CRP）水平。结果FBG、FINS和HOMA-R水平，糖尿病组比对照组显著升高（P〈0．05），而吡格列酮可以明显降低糖尿病大鼠的水平，差异有统计学意义（P〈0．05）；OGTF实验结果显示：糖尿病大鼠餐后血糖水平明显升高（P〈0．05），吡咯列酮明显减低糖尿病大鼠餐后血糖水平差异有统计学意义（P〈0．05）；IL-1β、IL-6、TNF-α、CRP水平与正常对照组比较糖尿病组显著升高（P〈0．05），而吡格列酮可以明显降低糖尿病大鼠的水平，差异有统计学意义（P〈0．05）。结论吡格列酮可下调血清炎症因子的表达，改善胰岛素抵抗。

Effect of Pioglitazone on Serum Glycometabolism of Rats Inflammatory Mediators and with Type 2 Diabetes

Objective To study the effects of pioglitazone on serum inflammatory mediators and glycometabolism in rats with type 2 diabetes. Methods Rats with type 2 diabetes model were established by injection of streptozotoein and fed with high fat and high calorie diet. These rats were divided into 2 groups： diabetes group （n = 10）, Pioglitazone group （nr = 10, 10 mg·kg-1· d-1 ）. Healthy Wistar rats were chosed as the control group （n = 10）. All rats were gavage for 8 weeks by the same volume of saline. The effect of Pioglitazone on fasting blood glucose （FBG）, fasting insulin （INS）, oral glucose tolerance test （OGT-F） were tested ; calculating insulin resistance index （HOMA-IR）. C reactive protein （ CRP）, interleuk in-113 （ IL-113）, interleuk in-6 （ IL-6 ） and tumor necrosis factor-c~ （TNF-ct） in type 2 diabetic rats were observed. Results Levels of FBG, FINS, and HOMA-R diabetic group were higher than those of the control group （P 〈 0.05）. Pioglitazone could significantly reduce these indicators in diabetic rats （ P 〈 0.05 ）. The result of OG33＂ showed that blood glucose level of rats in the diabetic group was higher than that of the control group （P 〈 0.05 ）, and pioglitazone could significantly reduce blood glucose levels of diabetic rat （P 〈 0. 05 ）. The levels of serum IL-113, IL-6, TNF-α of diabetic rat were higher than control group, and pioglitazone could significantly decreased those inflammatory mediators. Conclusion Pioglitazone can decrease inflammatory mediators levels, regulae glycometabolism and improve insulin resistance.